Nyxoah SA Form 6-K Summary
Business context and reporting period
Nyxoah SA furnished a Form 6-K on November 8, 2023, reporting unaudited third-quarter 2023 financial and operating results. The filing references a press release and a Third Quarter 2023 report as Exhibits 99.1 and 99.2, respectively, but the exhibit contents are not included in the provided text.
Financial and operating metrics
The filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, operating expenses, cash balance, or other financial metrics. These details are presumably contained in Exhibit 99.2.
Material changes versus the prior comparable period
The filing states that third-quarter 2023 financial and operating results were announced, but it does not provide comparative figures or describe material changes versus the third quarter of 2022 or the prior quarter.
Guidance, outlook, risks, contingencies, and unusual items
The provided filing text does not include guidance, outlook commentary, risk disclosures, contingencies, or unusual items. The referenced exhibits may contain additional management commentary and disclosures.
Important facts to verify
- Review Exhibit 99.2 for third-quarter 2023 revenue, net loss, cash flow, cash balance, liquidity, debt, and operating metrics.
- Verify year-over-year and sequential changes in financial and operating performance.
- Review Exhibit 99.1 and Exhibit 99.2 for updated guidance, clinical or commercial developments, risks, and contingencies.
- Note that Exhibit 99.2 is incorporated by reference into the company’s specified Form S-8 and Form F-3 registration statements, while Exhibit 99.1 is furnished and generally not deemed filed under Section 18 of the Exchange Act.